Buffett’s Berkshire cuts stakes in U.S. drugmakers, invests in drug
© Reuters. FILE PHOTO: Berkshire Hathaway Chairman Warren Buffett walks through the exhibit hall as shareholders gather to hear from the billionaire investor at Berkshire Hathaway Inc’s annual shareholder meeting in Omaha, Nebraska, U.S., May 4, 2019. REUTERS/Scott
(Reuters) – Warren Buffett’s Berkshire Hathaway (NYSE:) Inc said on Monday it eliminated its investment in Merck & Co and reduced its stakes in Abbvie Inc and Bristol-Myers Squibb (NYSE:) Co, as it pared its overall stock market investments.
The changes were disclosed in a regulatory filing detailing Berkshire’s U.S.-listed holdings as of Sept. 30.
Berkshire also disclosed new investments in Royalty Pharma Plc, which buys pharmaceutical royalties, and flooring retailer Floor & Decor Holdings (NYSE:) Inc.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Read More: Buffett’s Berkshire cuts stakes in U.S. drugmakers, invests in drug